Artera Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI
SAN FRANCISCO—-Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launches publicly today with $90M in funding. The investment comes from a syndicate of prominent tech and healthcare investors, comprised of seven institutions (Coatue, Johnson & Johnson Innovation – JJDC, Inc., Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, The Factory) and 11 angel investors (Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, Michael Driscoll).
“We are thrilled to support Artera as a pioneer in computational diagnostics for an important therapeutic area.”
Artera’s flagship test is the ArteraAI Prostate Test, the first test to predict therapy benefit in localized prostate cancer. The investment will help distribute this test in the U.S. and internationally. The company also plans to use the funding to invest in the development of tests to support therapy personalization in other cancers.
“The American Cancer Society estimates that more than 288,000 new cases of prostate cancer will arise in 2023, with more than 34,000 deaths. AI has given clinicians and patients a powerful weapon in the fight against this disease,” said Andre Esteva, co-founder and CEO of Artera. “Clinicians can now leverage Artera’s unique test to prognosticate patient outcomes and personalize treatment decisions.”
“We are honored to be part of what we believe to be one of the greatest advances in prostate oncology in the last 20 years,” said Marc Benioff, CEO of Salesforce.
“In the last 18 months, Artera’s AI-informed approach to personalized cancer treatment has unlocked commercial and regulatory traction well ahead of genomic competitors,” said Stephen Cho, Partner at Coatue. “We are thrilled to support Artera as a pioneer in computational diagnostics for an important therapeutic area.”
This announcement comes on the heels of Artera’s recently released, highlighting that the prognostic biomarker was validated across six phase III randomized trials. The study further demonstrated the ability of Artera’s multimodal artificial intelligence prognostic biomarker to help enable personalized, shared decision-making for patients and clinicians.
The ArteraAI Prostate Test is a clinically available, laboratory-developed test. For more information or to order the test please visit artera.ai.
ABOUT ARTERA
Artera is a leading precision medicine company developing AI tests to personalize therapy for cancer patients. Their test provides risk stratification and prediction of therapeutic benefit, including the first-ever predictive test for localized prostate cancer. It is clinically available through a CLIA-certified laboratory in Jacksonville, Florida, and can be ordered online at artera.ai.
